AUG 18, 2026 · PHASE 1/2 TRIAL
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
ClinicalTrials.gov
Phase 1/2 safety and tolerability trial in an active recruitment phase with no results posted; this is a planned study registration documenting trial design and safety endpoints only.
Reported
Planned enrollment240
Study phasePhase 1/Phase 2
Primary outcome: adverse eventsUp to approximately 2 years